FormBlends' platform extends beyond GLP-1 receptor agonists into the broader peptide therapy landscape, which reached $140.86 billion globally in 2025 and is projected to grow to $260.25 billion by ...

FormBlends' platform extends beyond GLP-1 receptor agonists into the broader peptide therapy landscape, which reached $140.86 ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Voters in Benin will vote Sunday to elect a new president as outgoing leader Patrice Talon steps down after a decade in power ...

Introduction Skin rash is the most common adverse effect in patients with cancer receiving epidermal growth factor receptor inhibitors (EGFRIs), which can impair quality of life and lead to treatment ...